A modular platform for infectious disease surveillance at point-of-need.

摘要 我们建议开发一个用于丝状病毒差异分子鉴定的需求点系统， 症状相似的感染我们的目标是实现快速、灵敏和特异性地鉴定可耐受的 感染，以减少医院风险和提高爆发反应。该平台将同时测试12个 使用模块化微流体设计，在属和菌株水平上进行基因组标记， 更新和扩展。在第一阶段，我们将开发一种泛丝状病毒（pFi）的检测方法，然后扩大 第二阶段的面板和系统集成。扩大的样本组将添加泛黄病毒（pFa）和泛疟原虫 (pPa)检测以及针对埃博拉、马尔堡、登革热、黄热病和疟疾的菌株特异性靶标。应变 特定的检测将有助于在疫情爆发期间更好地对患者进行分诊/治疗，并改善疾病监测， 非爆发设置。 该试剂盒将需要50 μL全血样本，并将在30分钟内实现高度特异性检测。 为了实现这一目标，我们将联合收割机Redbud Labs在微流体和系统方面的专业知识与诊断技术相结合。 PATH（华盛顿州西雅图）诊断程序的开发专业知识，以及VHF测试/处理 波士顿大学康纳实验室（NEIDL的BSL-4设施的一部分）的能力。

ABSTRACT We propose to develop a point-of-need system for differential molecular identification of filoviruses from syndromically similar infections. Our goal is to enable rapid, sensitive, and specific identification of quarantinable infections to reduce nosocomial risk and improve outbreak response. The platform will simultaneously test 12 genomic markers at the genus and strain level using a modular microfluidic design that allows for rapid panel update and expansion. In Phase I we will develop an assay for pan-filovirus (pFi), followed by expansion of the panel and system integration in Phase II. The expanded panel will add pan-flavivirus (pFa) and pan-Plasmodium (pPa) detection as well as strain-specific targets for Ebola, Marburg, Dengue, Yellow Fever, and Malaria. Strain specific tests will enable better patient triage/treatment during an outbreak and improve disease surveillance in non-outbreak settings. The panel will require a 50 μL sample of whole blood and will achieve highly specific detection in < 30 minutes. To achieve this goal, we will combine Redbud Labs’ expertise in microfluidics and systems with the diagnostic development expertise of the Diagnostics Program at PATH (Seattle, WA), and the VHF testing/processing capabilities of the Connor Lab at Boston University (part of the BSL-4 facilities at NEIDL).